LELIMA PHARMA

Active

Private limited companyfounded 2018active for 8 yearsRue Croix Thomas 6, 1341 Ottignies-Louvain-la-Neuve, BelgiumKBO/BCE: BE 0691.649.590

Summary

LELIMA PHARMA has been active since 2018 and the Belgian Official Gazette contains no insolvency or warning signals. The 2026 annual accounts show equity of €247,899 and a net result of €54,519. Equity is growing by about 32% per year across the filed financial years. Its solvency ranks better than 19% of 329 sector peers (NACE 70, financial year 2026). The computed 12-month bankruptcy probability is below 0.1% (very low).

Risk analysisFollow Report Compare

LELIMA PHARMAActiveChecked score 93/100

Risk analysis Report Compare

Activity

Business and other management consultancy

NACE 70200

1 site

Size

€1.3mtotal assets 2026

Equity: €247,899
Profit: €54,519

Turnover not published (abbreviated or micro format)

Financial health

93 Excellent Checked score 2026

Bankruptcy probabilitywithin 12 months: < 0.1%

Structure

Holdings: 1

2026 accounts 40 days early3 deeds in the Belgian Official Gazette

Why 93lowers riskSize: total assets €1.3mSector: Activities of head offices; management consultancy activities (NACE 70)Figures for financial year 2026 (filed 21-09-2026)Liquidity: current ratio 1.39, cash €142,665Show the evidence

Checked score

Score 2026

93 / 100

Excellent

Probability in this band: under 0.55%

Financially better than 46% of its sector peers (NACE 70, micro)

Every signal that counts is listed under Signals.

Financial strength · tick = 2025

Average

Solvency 44-56

equity 19.2% of total assets

Liquidity 61-39

short-term debt 14.3% · cash 11.0%

Profitability 74-22

return on assets 4.2%

Bankruptcy probability, 12 months

< 0.1% Very low

0%0.5%1.5%4%10%≥ 25%

Fewer than 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).

Sector median 0.1% (48,416 companies, NACE 70, micro)

Last 24 months 11-2024: < 0.1%highest value 12-2024: < 0.1%● unchanged vs 11-2024 01-2025: < 0.1%● unchanged vs 12-2024 02-2025: < 0.1%● unchanged vs 01-2025 03-2025: < 0.1%● unchanged vs 02-2025 04-2025: < 0.1%● unchanged vs 03-2025lowest value 05-2025: < 0.1%● unchanged vs 04-2025 06-2025: < 0.1%● unchanged vs 05-2025 07-2025: < 0.1%● unchanged vs 06-2025 08-2025: < 0.1%● unchanged vs 07-2025 09-2025: < 0.1%● unchanged vs 08-2025 10-2025: < 0.1%● unchanged vs 09-2025 11-2025: < 0.1%● unchanged vs 10-2025 12-2025: < 0.1%● unchanged vs 11-2025 01-2026: < 0.1%● unchanged vs 12-2025 02-2026: < 0.1%● unchanged vs 01-2026 03-2026: < 0.1%● unchanged vs 02-2026 04-2026: < 0.1%● unchanged vs 03-2026 05-2026: < 0.1%● unchanged vs 04-2026 06-2026: < 0.1%● unchanged vs 05-2026 07-2026: < 0.1%● unchanged vs 06-2026 08-2026: < 0.1%● unchanged vs 07-2026 09-2026: < 0.1%● unchanged vs 08-2026 10-2026: < 0.1%● unchanged vs 09-2026

Credit of up to €23,000 on 30-day terms is acceptable

Liquidity tight (current ratio 1.39, compared with 15.86 in 2025, below the usual 1.5; short-term debt: 14.3% and cash: 11% of total assets), and 80.8% of the assets are financed with debt and provisions.

How it is calculated

The band follows from the bankruptcy probability, on a scale where 10 more points roughly halve it:

75-100	Excellent	under 0.55%
60-74	Healthy	0.55% to 1.5%
45-59	Fair	1.5% to 4.2%
25-44	Weak	4.2% to 15.0%
0-24	Critical	over 15.0%

Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 70, micro): better than 23% on solvency, 53% on liquidity, 38% on profitability and 72% on growth.

The bankruptcy probability was computed on 23-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.

Some facts cap the score, however low the probability. Negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late hold it at Fair at most (59); two missing filings, at Weak (44). An ongoing judicial reorganisation or the company's end (bankruptcy, dissolution, liquidation) holds it at Critical at most (24).

Credit check for your own amount and term

Show the recommended maximum and see how the verdict changes with amount, term and advance.

Signals

Six signals.

lowers riskraises riskneutral

Size: total assets €1.3m

Companies of this size fail less often; how much that weighs depends on the rest of its profile.

NBB · annual accounts

Sector: Activities of head offices; management consultancy activities (NACE 70)

KBO

Figures for financial year 2026 (filed 21-09-2026)

NBB · annual accounts

Liquidity: current ratio 1.39, cash €142,665

NBB · annual accounts

Weak solvency vs sector

Solvency (equity / total assets) is in the sector's weakest quartile: better than 19% of 329 sector peers (2026).

NBB · sector comparison

Position among 329 sector peers

Solvency

better than 19%

← weakest strongest →

Latest accounts filed on time

The financial year that closed on 31-03-2026 was due by 31-10-2026 and was filed on 21-09-2026, 40 days ahead of the deadline.

NBB · 8 filings

Deviation from the deadline

2026

40 days early

2025

32 days early

2024

1 day early

2023

on the day

2022

68 days early

2021

75 days early

2020

71 days early

← before the deadline after the deadline →

tick = median of all Belgian filingsring = median in the sector

This company filed its last 7 accounts on average 41 days before the deadline; the sector median (NACE 70) for financial year 2024 is 9 days before the deadline, and 32% of those companies filed late.

Searched, nothing found (2)

Next filing not due yet

The next financial year closes on 31-03-2027 and is due by 31-10-2027. Nothing is late today. The company usually files around 29 September (4 of the last 5 filed years within 32 days of that day).

Companies Code · seven months

Where today falls in the filing period

24-10-2026 today31-03-2027 year end31-10-2027 deadline

No strike-offs in the KBO publications

Searched since 2021.

KBO publications · our coverage

21-09-2026 Annual accounts filedfinancial year 2026 · abbreviated…
20-04-2026 Director resignation · General meetingDirector appointment · Permanent representative
31-03-2026 Highest result from 2019 to 2026net €54,519 ▲20.1%

Key points

Caution: Among the weakest 19% on solvencysector median 57.3% · 329 companies 19.2% View
Positive: Always filed on timeaccounts within the deadline every year 8 years View
Positive: 8 profitable years in a rowprofit 2026: €54,519 8 years View
Positive: Equity rose in 2026from €193,380 to €247,899 ▲ 28.2% View

By topic

Financials

Financial year: 2026
Total assets: €1.3m
Profit: €54,519
Solvency: 19.2%

Total assets▲ 526%

Net result

20192026

Go to Financials

Network & group

Subsidiaries: 1

1 subsidiary

Go to Network & group

Timeline

Events: 14
Since: 2019
Next accounts: by 31-10-2027

31-03-2026Equity above €200,000
29-09-2025Annual accounts filed
31-03-2025Equity above €150,000

Go to Timeline

Company details

Sites: 1

Legal form: Private limited company
Activity: Business and other management consultancyNACE 70200
Founded: 01-03-2018
Year ends: 31-03
Peppol: Reachable for e-invoices

Go to Company details

Key facts about LELIMA PHARMA

What is the company number of LELIMA PHARMA?: 0691.649.590. In Belgium the VAT number is the company number with BE in front: BE 0691.649.590.
Where is LELIMA PHARMA based?: The registered office is at Rue Croix Thomas 6, 1341 Ottignies-Louvain-la-Neuve.Company details
What does LELIMA PHARMA do?: According to the KBO register, the main activity is business and other management consultancy (NACE 70200).
What is the legal form of LELIMA PHARMA?: Private limited company (BV).
When was LELIMA PHARMA founded?: On 01-03-2018.
Is LELIMA PHARMA still active?: Yes, LELIMA PHARMA is an active enterprise in the KBO register.
What is the turnover of LELIMA PHARMA?: Not stated in the processed annual accounts. The abridged format for small companies does not require turnover.Financials
Is LELIMA PHARMA profitable?: In financial year 2026, LELIMA PHARMA made a profit of €54,519.
Where can I find the annual accounts of LELIMA PHARMA?: LELIMA PHARMA filed 8 annual accounts with the National Bank of Belgium, the latest for financial year 2026.
When are the next annual accounts of LELIMA PHARMA due?: By 31-10-2027, for financial year 2027.Timeline